Pfizer, Merck trial antiviral combos amid concerns over resistance to COVID-19 pills
Summary by Ground News
FDA greenlighted Paxlovid and molnupiravir as the first oral COVID-19 therapies for at-home use last month. However, the mutations that allow viruses to evade the antivirals are a real danger for drugs. The researchers from Pfizer (PFE) and Merck (MRK) have rebuffed such fears noting that they did not see drug resistance during their trials.4 months ago
News Articles
Time & Location
Sources are mostly out of (0)
